Key result
In patients with atrial fibrillation, rate-control treatment with β-blockers (HR 0.76; 95% CI 0.74-0.78) or calcium channel blockers reduced mortality risk compared to no rate-control medication.
Why the study?
Do rate-control drugs (β-blockers, calcium channel blockers, or digoxin) reduce all-cause mortality in patients with atrial fibrillation compared to no rate-control treatment?
Population
269,921 patients with atrial fibrillation from the National Health Insurance Research Database in Taiwan.
Comparison
Rate-control drugs vs No rate-control drug (n=168,678)
Design
Cohort
Follow-up
4.9±3.7 years
Authors
Loading...
Rate-control with β-blockers or CCBs was associated with lower AF mortality; leaves open causal benefit pending randomized confirmation.
Cohort (n=269,921)
Do rate-control drugs (β-blockers, calcium channel blockers, or digoxin) reduce all-cause mortality in patients with atrial fibrillation compared to no rate-control treatment?
Hazard Ratio: 0.76 (95% CI 0.74–0.78)
In a nationwide cohort of patients with atrial fibrillation, rate control with beta-blockers or calcium channel blockers was associated with lower mortality, whereas digoxin was associated with higher mortality.
Chao et al. (2015) conducted a cohort in Atrial fibrillation (n=269,921). Rate-control treatment (β-blockers, calcium channel blockers, or digoxin) vs. No rate-control drug was evaluated on All-cause mortality (HR 0.76, 95% CI 0.74-0.78). In patients with atrial fibrillation, rate-control treatment with β-blockers (HR 0.76; 95% CI 0.74-0.78) or calcium channel blockers reduced mortality risk compared to no rate-control medication.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: